Products | July 26, 2010

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

Related Content

Focused Ultrasound Foundation Chairman Receives Honors
News | Ultrasound Imaging
Focused Ultrasound Foundation Chairman Receives Honors

July 13, 2026 — Neal F. Kassell, MD, founder and chairman of the Focused Ultrasound Foundation, received the inaugural ...

Time July 13, 2026
arrow
News | Contrast Agents
Bayer’s Ambelvist Receives FDA Approval for Contrast-Enhanced MRI

June 15, 2026 – Bayer has announced that the U.S. Food and Drug Administration (FDA) approved Ambelvist (gadoquatrane) ...

Time June 16, 2026
arrow
Bracco, ACIST Medical Systems Receive FDA Clearance of ACIST Pro Diagnostic System
News | FDA
Bracco, ACIST Medical Systems Receive FDA Clearance of ACIST Pro Diagnostic System

May 18, 2026 — ACIST Medical Systems, a Bracco company, has received U.S. Food and Drug Administration (FDA) clearance ...

Time May 18, 2026
arrow
cardiovascular ultrasound, cardiac imaging
News | ASE
ASE Releases New Guideline for Cardiac Ultrasound Artifacts Released

May 4, 2026 — The American Society of Echocardiography (ASE) has released a new guideline that provides guidance for ...

Time May 05, 2026
arrow
Bayer, MRI, injector, FDA
News | Magnetic Resonance Imaging (MRI)
FDA Grants 510(k) Clearance for Expanded Capabilities of MR Injection System

March 4, 2026 — The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Bayer for the expanded ...

Time March 04, 2026
arrow
Philips Enters Agreement to Acquire SpectraWAVE
News | Cardiac Imaging
Philips Enters Agreement to Acquire SpectraWAVE

Dec. 15, 2025 — Royal Philips has entered into an agreement to acquire SpectraWAVE, Inc., an innovator in enhanced ...

Time December 18, 2025
arrow
Sponsored Content | Videos | Radiology Business
VIDEO: Talking Trends with Bayer Radiology — Navigating Market Disruptions to Your CT Suite

Bayer Radiology’s Barbara Ruhland and Thom Kinst discuss how radiology departments can address the many different ...

Time October 09, 2025
arrow
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives
News | Ultrasound Imaging
Study: Contrast-Enhanced Ultrasound is Safe, Saves lives

May 14, 2025 — A comprehensive new study based on nationwide claims data from more than 11 million patients shows that ...

Time May 14, 2025
arrow
Bracco and Blue Earth Diagnostics has announced the appointment of Marco Campione as new CEO, effective immediately. Campione succeeds David Gauden, D. Phil., who now assumes the role of CEO of Bracco subsidiary Blue Earth Therapeutics.
News | Radiology Business
Blue Earth Diagnostics, a Bracco Company, Appoints Marco Campione as Chief Executive Officer

July 9, 2024 — Bracco and Blue Earth Diagnostics, a Bracco company and recognized leader in the development and ...

Time July 09, 2024
arrow
Swedish biotech company Ascelia Pharma has announced its liver imaging drug candidate, Orviglance, significantly improved visualization of focal liver lesions, having successfully met the primary endpoint in the pivotal Phase 3 study, SPARKLE. CEO Magnus Corftizen shown here, offered an update on the first-in-class contrast agent for use in liver MRI in patients with severely impaired kidney function which has been granted FDA Orphan Drug Designation.
News | Contrast Media
Ascelia Pharma Meets Primary Endpoint in Phase 3 Study of Orviglance Liver Imaging Contrast Agent Drug Candidate

May 8, 2024 — Swedish biotech company Ascelia Pharma AB has announced that its liver imaging drug candidate, Orviglance ...

Time May 08, 2024
arrow
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now